Journal article
Efficacy and safety of namilumab, a human monoclonal antibody against granulocyte-macrophage colony-stimulating factor (GM-CSF) ligand in patients with rheumatoid arthritis (RA) with either an inadequate response to background methotrexate therapy or an inadequate response or intolerance to an anti-TNF (tumour necrosis factor) biologic therapy: a randomized, controlled trial
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Version of record, zip, 1.1MB)
-
(Version of record, pdf, 1.4MB)
-
- Publisher copy:
- 10.1186/s13075-019-1879-x
Authors
Bibliographic Details
- Publisher:
- BioMed Central Publisher's website
- Journal:
- Arthritis Research and Therapy Journal website
- Volume:
- 21
- Article number:
- 101
- Publication date:
- 2019-04-18
- Acceptance date:
- 2019-03-26
- DOI:
- EISSN:
-
1478-6362
- ISSN:
-
1478-6355
Item Description
- Keywords:
- Pubs id:
-
pubs:985109
- UUID:
-
uuid:8e8f931f-4191-41e2-a6d9-4814b00c537e
- Local pid:
- pubs:985109
- Source identifiers:
-
985109
- Deposit date:
- 2019-03-27
Terms of use
- Copyright holder:
- Taylor, PC et al
- Copyright date:
- 2019
- Notes:
- © Taylor, PC et al. 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License.
- Licence:
- CC Attribution (CC BY)
Metrics
If you are the owner of this record, you can report an update to it here: Report update to this record